All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @ang.slater on TikTok · 79s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @ang.slater's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Do not take Zepbound, these are the side effects of Zepbound and other GLP one medications they didn't warn you about.
  2. 0:05I'm Ang, I lost 100 pounds in 11 months on some Agletide, I am sharing everything I know so be sure to follow to learn more.
  3. 0:10First, you will have to buy a new wardrobe because none of your clothes will fit you anymore.
  4. 0:14Once you figure out your new size, you will never get to waste your time trying on clothes ever again because you'll be able to just buy off the rack and things will just fit you.
  5. 0:23Your schedule gets interrupted because you are now no longer having food noise and thinking about food 24 or 7,
  6. 0:29so it's like, what am I going to do with all this extra time?
  7. 0:31This one's been especially annoying for me, if you're a PCOS girlie, your cycles may become regular,
  8. 0:37which means that you'll get your period every month.
  9. 0:39Ew.
  10. 0:40People will become extra nice to you and give you attention, which is pretty awkward when you've spent most of your life feeling invisible.
  11. 0:47They can help improve your blood pressure, cholesterol, blood sugar, inflammation,
  12. 0:51so that means that you wasted money on that pill organizer you bought because you may no longer need it.
  13. 0:55And they even have the audacity to give you confidence.
  14. 0:58I'm out here as a 35 year old mother of a toddler doing the absolute most and feeling myself,
  15. 1:04even though I look like Adam Sandler most days.
  16. 1:07They may reduce your cravings for alcohol and other addictive tendencies.
  17. 1:10Like you didn't tell me I was going to be getting so healthy.
  18. 1:13So yeah, do not click the link in my bio where you can get access to these medications because you may have these terrible side effects too.

@ang.slater's Zepbound warnings fact-checked

Ang Slater

TikTok creator

1.2M viewsWatch on TikTok

Quick answer

Tirzepatide (Zepbound) is a dual GIP and GLP-1 receptor agonist FDA-approved for chronic weight management in adults with obesity or overweight with a weight-related comorbidity. The SURMOUNT-1 trial demonstrated up to 22.5% mean body weight reduction over 72 weeks, with clinically meaningful improvements in blood pressure, triglycerides, and glycemic markers. Serious risks including gastrointestinal adverse events affecting the majority of users, a boxed warning for thyroid C-cell tumors based on animal data, and the potential for significant weight regain after discontinuation are not addressed in this video.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded TirzepatideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Tirzepatide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 7 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @ang.slater's Zepbound warnings fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Tirzepatide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this tirzepatide video claims cluster

Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@ang.slater's Zepbound warnings fact-checked" from Ang Slater. We read the clip as a GLP-1 social video fact-checks claim about Compounded Tirzepatide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Tirzepatide (Zepbound) is a dual GIP and GLP-1 receptor agonist FDA-approved for chronic weight management in adults with obesity or overweight with a weight-related comorbidity.

The reason this review is not generic is the source wording and the canonical claim label "glp1 the side effects of glp 1s i was never warned about lon." In this clip, the useful excerpt is: "Do not take Zepbound, these are the side effects of Zepbound and other GLP one medications they didn't warn you about." That wording changes the review because it points to Compounded Tirzepatide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Tirzepatide Once Weekly for the Treatment of Obesity (2022), Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (2024), and Tirzepatide for Obesity Treatment and Diabetes Prevention (2025), plus the creator's own wording. Compounded Tirzepatide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Over 60% of participants in SURMOUNT-1 experienced gastrointestinal adverse events including nausea, vomiting, and diarrhea.
People who land here are usually comparing the Compounded Tirzepatide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Tirzepatide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Tirzepatide (Zepbound) is a dual GIP and GLP-1 receptor agonist FDA-approved for chronic weight management in adults with obesity or overweight with a weight-related comorbidity.

FormBlends verdict

Compounded Tirzepatide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Tirzepatide (Zepbound) is a dual GIP and GLP-1 receptor agonist FDA-approved for chronic weight management in adults with obesity or overweight with a weight-related comorbidity. The SURMOUNT-1 trial demonstrated up to 22.5% mean body weight reduction over 72 weeks, with clinically meaningful improvements in blood pressure, triglycerides, and glycemic markers. Serious risks including gastrointestinal adverse events affecting the majority of users, a boxed warning for thyroid C-cell tumors based on animal data, and the potential for significant weight regain after discontinuation are not addressed in this video.
  • SURMOUNT-1 (Jastreboff et al., 2022, NEJM) documented mean weight loss up to 22.5% of body weight with tirzepatide over 72 weeks, making large weight loss plausible but not typical for everyone.
  • Over 60% of participants in SURMOUNT-1 experienced gastrointestinal adverse events including nausea, vomiting, and diarrhea. This video mentions none of them.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.

Review Compounded Tirzepatide

What You'll Learn

  • SURMOUNT-1 (Jastreboff et al., 2022, NEJM) documented mean weight loss up to 22.5% of body weight with tirzepatide over 72 weeks, making large weight loss plausible but not typical for everyone.
  • Over 60% of participants in SURMOUNT-1 experienced gastrointestinal adverse events including nausea, vomiting, and diarrhea. This video mentions none of them.
  • Tirzepatide carries an FDA boxed warning for thyroid C-cell tumors observed in animal studies. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.
  • The cardiometabolic improvements described (blood pressure, cholesterol, blood sugar) are real and trial-supported, but deprescribing existing medications should only happen under physician supervision, not as a self-managed outcome.
  • GLP-1 effects on alcohol and addictive cravings in humans remain an early-stage research area. Klausen et al. (2023, JCI Insight) showed effects in animal models, but this is not an approved use and human evidence is not yet sufficient to make routine claims.
  • Weight regain after stopping tirzepatide is well-documented. A 2023 study (Aronne et al., NEJM) showed participants regained most lost weight within a year of discontinuation. Long-term use or lifestyle infrastructure is typically required to maintain results.
  • The creator refers to the drug as 'Agletide,' which is not a real drug name. The medication she used is tirzepatide (brand name Zepbound). Misnaming medications in high-reach health content creates real confusion for people researching treatment options.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @ang.slater actually say?

This is a comedic reverse-psychology video. @ang.slater frames weight loss benefits as fake "side effects" to drive people toward her bio link. She claims Zepbound caused her to lose 100 pounds in 11 months, eliminated food noise, regulated her PCOS cycles, improved blood pressure and cholesterol, reduced alcohol cravings, and gave her back confidence. The joke format is entertaining, but the underlying claims are real health assertions that deserve real scrutiny.

Worth noting upfront: she refers to a drug called "Agletide," which is not a real medication name. She almost certainly meant tirzepatide, the active ingredient in Zepbound. That kind of casual name-mangling in a 1.2 million view video matters, because people are searching for what they think they heard.

Does the science back this up?

More than you might expect. The core claims here are not made up. Clinical data on tirzepatide is actually quite strong, and several of her "side effects" track directly to published trial outcomes. But the framing erases a lot of real, serious adverse effects that patients absolutely should know about before starting.

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) found tirzepatide produced mean weight loss of up to 22.5% of body weight over 72 weeks in adults with obesity. Losing 100 pounds in 11 months is at the aggressive end of that range, but not impossible depending on starting weight. The trial also documented meaningful improvements in cardiometabolic markers including blood pressure, triglycerides, and fasting glucose, which matches her claims about the pill organizer becoming unnecessary. The SURMOUNT-2 trial extended these findings to patients with type 2 diabetes.

On food noise: GLP-1 and GIP receptor agonism does appear to reduce appetite signals centrally, not just in the gut. A 2023 review by Müller et al. in Nature Metabolism described tirzepatide's dual agonism as producing stronger appetite suppression than GLP-1 single agonists, consistent with her description of food noise disappearing.

What did they get wrong (or right)?

The PCOS cycle regulation claim is the most scientifically interesting one she raised, and she gets partial credit. Insulin resistance is a major driver of cycle irregularity in PCOS, and weight loss combined with improved insulin sensitivity can restore ovulation. A 2023 study by Elkind-Hirsch et al. in Fertility and Sterility specifically examined semaglutide in PCOS patients and found improved cycle regularity. The same mechanism plausibly applies to tirzepatide, but there is no large randomized trial specifically on tirzepatide and PCOS cycles yet. So: biologically plausible, not yet definitively proven for this specific drug.

The alcohol and addiction claim is the most oversimplified. She says they "may reduce your cravings for alcohol and other addictive tendencies" as if it is a given. The evidence here is early and mixed. A 2023 study by Klausen et al. in JCI Insight found GLP-1 receptor agonists reduced alcohol intake in rodent models, and some case reports and small human studies suggest reduced cravings. But this is not an approved indication, the mechanism in humans is not established, and presenting it as a casual bonus effect is irresponsible at a 1.2 million view scale.

What she got completely wrong by omission: nausea, vomiting, diarrhea, and constipation affect a significant portion of tirzepatide users, particularly during dose escalation. The SURMOUNT-1 trial reported gastrointestinal adverse events in over 60% of participants. There is also a boxed warning for thyroid C-cell tumors in animal studies. None of that makes it into the joke.

What should you actually know?

The benefits she describes are real and documented. Tirzepatide is one of the most effective weight loss agents studied in a clinical trial setting, and the downstream cardiometabolic improvements are not trivial. For people managing obesity-related conditions, these are meaningful outcomes.

But this video is structured as a sales funnel. The last line tells you not to click the link in her bio while obviously inviting you to do exactly that. That framing, combined with the "side effects" joke, strips away the context that makes informed consent possible.

If you are considering a GLP-1 medication, the conversation should include: your personal history of pancreatitis, thyroid cancer, or MEN2 syndrome; a realistic picture of GI side effects during titration; the fact that muscle mass loss can accompany rapid weight loss without adequate protein intake and resistance training; and what happens when you stop the medication, because weight regain is common without ongoing treatment or lifestyle infrastructure. A licensed provider, not a TikTok bio link, is where that conversation belongs.

Bottom line on @ang.slater's claims

She is not making things up. The cardiometabolic benefits, appetite suppression, and PCOS cycle effects all have real scientific backing. Her personal result is dramatic but within the range of what trials have shown. The problem is the omission of genuine risks and the commercial structure wrapped around legitimate health information. Entertaining content. Incomplete health guidance.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Ang Slater · TikTok creator

1.2M views on this video

The side effects of GLP-1s I was never warned about 😱 #longervideos #zepbound #zepboundsavingscard #zepboundprovider #zepboundcoupon #zepboundcommunity #zepboundcoverage #tirzepatide #healthjourney

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about surmount-1 (jastreboff et al., 2022, nejm) documented mean weight loss?

SURMOUNT-1 (Jastreboff et al., 2022, NEJM) documented mean weight loss up to 22.5% of body weight with tirzepatide over 72 weeks, making large weight loss plausible but not typical for everyone.

What does the video say about over 60% of participants in surmount-1 experienced gastrointestinal adverse events?

Over 60% of participants in SURMOUNT-1 experienced gastrointestinal adverse events including nausea, vomiting, and diarrhea. This video mentions none of them.

What does the video say about tirzepatide carries an fda boxed warning for thyroid c-cell tumors?

Tirzepatide carries an FDA boxed warning for thyroid C-cell tumors observed in animal studies. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.

What does the video say about the cardiometabolic improvements described (blood pressure, cholesterol, blood sugar)?

The cardiometabolic improvements described (blood pressure, cholesterol, blood sugar) are real and trial-supported, but deprescribing existing medications should only happen under physician supervision, not as a self-managed outcome.

What does the video say about glp-1 effects on alcohol?

GLP-1 effects on alcohol and addictive cravings in humans remain an early-stage research area. Klausen et al. (2023, JCI Insight) showed effects in animal models, but this is not an approved use and human evidence is not yet sufficient to make routine claims.

What does the video say about weight regain after stopping tirzepatide?

Weight regain after stopping tirzepatide is well-documented. A 2023 study (Aronne et al., NEJM) showed participants regained most lost weight within a year of discontinuation. Long-term use or lifestyle infrastructure is typically required to maintain results.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Ang Slater, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.